Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01106742

Enrollment

Registered

2010-04-20

Start date

2009-03-31

Completion date

2011-07-31

Last updated

2011-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Keywords

Inflammatory, AbM, IBD

Brief summary

Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill) based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy volunteers after 12 days consumption, the aim in this study is to investigate whether same effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal inflammation will be measured in blood and feces of these patients.

Interventions

DIETARY_SUPPLEMENTAndoSan

AndoSan, 20mlx3, 12 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Moderate disease activity

Exclusion criteria

* No use of Imurel (Azathioprin) or anti-TNF treatment

Design outcomes

Primary

Measure	Time frame
The ultimate goal is to see whether the ABM can be used as additional treatment of IBD.	12 days

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026